^
CDKN2A overexpression
Estrogen Receptor Positive Breast Cancer
CDK6 inhibitor
Resistant
:
D
Nat Commun - 2 weeks - (New D)
CDKN2A overexpression
Estrogen Receptor Positive Breast Cancer
CDK4 inhibitor
Resistant
:
D
Nat Commun - 2 weeks - (New D)
ER positive
Estrogen Receptor Positive Breast Cancer
fulvestrant
Sensitive
:
A1
ER positive
Estrogen Receptor Positive Breast Cancer
exemestane
Sensitive
:
A1
ER positive
Estrogen Receptor Positive Breast Cancer
toremifene
Sensitive
:
A1
ER mutation
Estrogen Receptor Positive Breast Cancer
palbociclib
Sensitive
:
B
ER positive
Estrogen Receptor Positive Breast Cancer
palbociclib
Sensitive
:
B
ER mutation
Estrogen Receptor Positive Breast Cancer
fulvestrant
Sensitive
:
B
ER mutation
Estrogen Receptor Positive Breast Cancer
exemestane
Resistant
:
B
HSD17B2 overexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive
:
B
IGFBP7 overexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive
:
B
ER positive
Estrogen Receptor Positive Breast Cancer
RAD1901
Sensitive
:
B
ESR1 mutation
Estrogen Receptor Positive Breast Cancer
palbociclib
Sensitive
:
B
ER positive
Estrogen Receptor Positive Breast Cancer
Z-endoxifen hydrochloride
Sensitive
:
C2
ER positive
Estrogen Receptor Positive Breast Cancer
SAR439859
Sensitive
:
C2
ER positive
Estrogen Receptor Positive Breast Cancer
alpelisib
Sensitive
:
C2
ER positive
Estrogen Receptor Positive Breast Cancer
abemaciclib
Sensitive
:
C2
ER positive
Estrogen Receptor Positive Breast Cancer
ribociclib
Sensitive
:
C2
PTEN mutation
Estrogen Receptor Positive Breast Cancer
AZD5363
Sensitive
:
C2
ER positive
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive
:
C2
ER positive
Estrogen Receptor Positive Breast Cancer
anastrozole
Sensitive
:
C2
ER positive
Estrogen Receptor Positive Breast Cancer
letrozole
Sensitive
:
C2
ER positive
Estrogen Receptor Positive Breast Cancer
RG4733
Sensitive
:
C2
ER positive
Estrogen Receptor Positive Breast Cancer
SNDX-275
Sensitive
:
C2
ER positive
Estrogen Receptor Positive Breast Cancer
tamoxifen + goserelin acetate
Sensitive
:
C2
TP53 wild-type
Estrogen Receptor Positive Breast Cancer
ALRN-6924
Sensitive
:
C2
EPRS1 expression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive
:
C3
FTO expression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive
:
C3
CTDSP1 expression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive
:
C3
BIN3 expression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive
:
C3
ER positive
Estrogen Receptor Positive Breast Cancer
bevacizumab
Sensitive
:
C3
ER Y537S
Estrogen Receptor Positive Breast Cancer
fulvestrant
Sensitive
:
C3
CDK6 overexpression
Estrogen Receptor Positive Breast Cancer
fulvestrant
Resistant
:
C3
RSF1 amplification
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant
:
C3